PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
Objective: This study aims to compare the efficacy of docetaxel on PSA levels and to analyze the adverse events caused by docetaxel. Material & Methods: The study design was retrospective cohort. Participants were prostate cancer patients at Saiful Anwar Hospital who received androgen deprivati...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IKATAN AHLI UROLOGI INDONESIA
2025-01-01
|
| Series: | Jurnal Urologi Indonesia |
| Subjects: | |
| Online Access: | http://juri.urologi.or.id/juri/article/view/917 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841554168146296832 |
|---|---|
| author | Kurnia Penta Seputra Andri Kustono Muhammad Baihaqy Ibnu Hakim |
| author_facet | Kurnia Penta Seputra Andri Kustono Muhammad Baihaqy Ibnu Hakim |
| author_sort | Kurnia Penta Seputra |
| collection | DOAJ |
| description |
Objective: This study aims to compare the efficacy of docetaxel on PSA levels and to analyze the adverse events caused by docetaxel. Material & Methods: The study design was retrospective cohort. Participants were prostate cancer patients at Saiful Anwar Hospital who received androgen deprivation therapy with increased PSA level 3 times the nadir or 2 bone lesions or soft tissue lesions > 2cm. PSA levels were assessed monthly. Participants were grouped into 6 and 10 series regimens. Adverse events of nausea, diarrhea, alopecia, SGOT SGPT abnormailties, creatinine abnormalities, anemia, and neutropenia were observed. Statistical analysis was performed using a differential T-test. Results: A total of 32 participants were involved. The PSA levels between 6 and 10 series groups were as follows: 1st month (142.2 vs 28.24 ng/mL,p=0.000), 2nd month (101.78 vs 16.98 ng/mL,p=0.001), 3rd month (472.35 vs 13.95 ng/mL,p=0.439), 4th month (120.64 vs 4.0 ng/mL,p=0.180), 5th month (64.325 vs 24.6 ng/mL, p=0.015), 6th month (41.915 vs 20.7 ng/mL,p=0.497). Adverse events in the 6 and 10 series regimens were nausea (25% vs 81.25%), diarrhea (37.5% vs 50%), alopecia (6.25% vs 43.75%), SGOT SGPT abnormalities (25% vs 56.25%), creatinine abnormalities (6.25% vs 37.5%), anemia (18.75% vs 31.25%), leukocytosis (6.25% vs 0%), and neutropenia (25% vs 12.5%). Adverse events in 6 series regimen began to occur in 3rd series with 1 participant experiencing nausea, and the most were 3 participants experiencing diarrhea in 6th series. Adverse events in 10 series regimen began to occur in 4th series with 1 participant experiencing nausea, 1 participant experiencing SGOT SGPT abnormalities, 1 participant experiencing diarrhea, and the most were 4 participants experiencing nausea in the 9th series. Conclusion: The 10 series of docetaxel chemotherapy is not superior to 6 series. Adverse events are more prominent in the 10 series.
Keywords: Docetaxel, PSA, adverse events.
|
| format | Article |
| id | doaj-art-308055e2a9654c4188ca2b0dfe796949 |
| institution | Kabale University |
| issn | 0853-442X 2355-1402 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | IKATAN AHLI UROLOGI INDONESIA |
| record_format | Article |
| series | Jurnal Urologi Indonesia |
| spelling | doaj-art-308055e2a9654c4188ca2b0dfe7969492025-01-08T17:22:52ZengIKATAN AHLI UROLOGI INDONESIAJurnal Urologi Indonesia0853-442X2355-14022025-01-0132110.32421/juri.v32i1.917PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS Kurnia Penta Seputra0Andri Kustono1Muhammad Baihaqy Ibnu Hakim2Departmen of Urology, Faculty of Medicine/University of Brawijaya, Saiful Anwar Hospital, Malang.Departmen of Urology, Faculty of Medicine/University of Brawijaya, Saiful Anwar Hospital, Malang.Departmen of Urology, Faculty of Medicine/University of Brawijaya, Saiful Anwar Hospital, Malang. Objective: This study aims to compare the efficacy of docetaxel on PSA levels and to analyze the adverse events caused by docetaxel. Material & Methods: The study design was retrospective cohort. Participants were prostate cancer patients at Saiful Anwar Hospital who received androgen deprivation therapy with increased PSA level 3 times the nadir or 2 bone lesions or soft tissue lesions > 2cm. PSA levels were assessed monthly. Participants were grouped into 6 and 10 series regimens. Adverse events of nausea, diarrhea, alopecia, SGOT SGPT abnormailties, creatinine abnormalities, anemia, and neutropenia were observed. Statistical analysis was performed using a differential T-test. Results: A total of 32 participants were involved. The PSA levels between 6 and 10 series groups were as follows: 1st month (142.2 vs 28.24 ng/mL,p=0.000), 2nd month (101.78 vs 16.98 ng/mL,p=0.001), 3rd month (472.35 vs 13.95 ng/mL,p=0.439), 4th month (120.64 vs 4.0 ng/mL,p=0.180), 5th month (64.325 vs 24.6 ng/mL, p=0.015), 6th month (41.915 vs 20.7 ng/mL,p=0.497). Adverse events in the 6 and 10 series regimens were nausea (25% vs 81.25%), diarrhea (37.5% vs 50%), alopecia (6.25% vs 43.75%), SGOT SGPT abnormalities (25% vs 56.25%), creatinine abnormalities (6.25% vs 37.5%), anemia (18.75% vs 31.25%), leukocytosis (6.25% vs 0%), and neutropenia (25% vs 12.5%). Adverse events in 6 series regimen began to occur in 3rd series with 1 participant experiencing nausea, and the most were 3 participants experiencing diarrhea in 6th series. Adverse events in 10 series regimen began to occur in 4th series with 1 participant experiencing nausea, 1 participant experiencing SGOT SGPT abnormalities, 1 participant experiencing diarrhea, and the most were 4 participants experiencing nausea in the 9th series. Conclusion: The 10 series of docetaxel chemotherapy is not superior to 6 series. Adverse events are more prominent in the 10 series. Keywords: Docetaxel, PSA, adverse events. http://juri.urologi.or.id/juri/article/view/917Docetaxel, PSA, adverse events. |
| spellingShingle | Kurnia Penta Seputra Andri Kustono Muhammad Baihaqy Ibnu Hakim PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS Jurnal Urologi Indonesia Docetaxel, PSA, adverse events. |
| title | PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS |
| title_full | PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS |
| title_fullStr | PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS |
| title_full_unstemmed | PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS |
| title_short | PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS |
| title_sort | psa level and adverse events in sixth and tenth series docetaxel chemotherapy in castrate resistant prostate cancer crpc patients |
| topic | Docetaxel, PSA, adverse events. |
| url | http://juri.urologi.or.id/juri/article/view/917 |
| work_keys_str_mv | AT kurniapentaseputra psalevelandadverseeventsinsixthandtenthseriesdocetaxelchemotherapyincastrateresistantprostatecancercrpcpatients AT andrikustono psalevelandadverseeventsinsixthandtenthseriesdocetaxelchemotherapyincastrateresistantprostatecancercrpcpatients AT muhammadbaihaqyibnuhakim psalevelandadverseeventsinsixthandtenthseriesdocetaxelchemotherapyincastrateresistantprostatecancercrpcpatients |